In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Sana Biotechnology, with a price target of $11.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Emily Bodnar’s rating is based on several promising developments within Sana Biotechnology. The company has reported positive results from its UP421 program, which involves a hypoimmune allogeneic islet cell transplant for type 1 diabetes patients. The study demonstrated successful islet cell survival and function without the need for immunosuppression, which is a significant advancement in the treatment of type 1 diabetes. This success serves as proof of concept for the broader application of their HIP platform.
Additionally, Sana is advancing its SC451 program, which is a one-time iPSC-derived HIP-modified islet cell therapy. The company has had a positive pre-IND FDA INTERACT meeting, indicating a clear path toward an IND filing in 2026. Sana’s strong financial position, bolstered by recent fundraising efforts, positions it well to achieve its development goals. The scalability of SC451, which does not require immunosuppression, represents a substantial market opportunity, further supporting the Buy rating.
In another report released on August 4, Citi also reiterated a Buy rating on the stock with a $15.00 price target.